Updated:
Lygos
Lygos, founded by Jay Keasling, engineers microbes to produce industrial chemicals from sugars, backed by over $230M in venture funding.
Lygos
Lygos was founded in 2010 in Berkeley, California, spinning out of the synthetic biology tradition of the Keasling Lab at UC Berkeley. Co-founders Eric Steen and Jeffrey Dietrich built the company alongside advisor and scientific founder Jay Keasling, one of the field's most cited pioneers. The firm is not a family office but an industrial biotechnology company developing microbial fermentation processes to manufacture specialty chemicals at commercial scale. The company engineers yeast and other microorganisms to produce high-value organic acids and chemical intermediates that traditionally come from petroleum. Its core technology platform converts low-cost sugars into malonic acid derivatives and other specialty compounds. Verified product lines include bio-based malonic acid used in fragrance fixatives, agricultural nutrient delivery systems, and biodegradable polymer precursors. The firm targets markets in North America and Asia, operating a dual-headquarters structure from Berkeley, California and Seoul, South Korea. Lygos has disclosed more than $230 million in total equity funding from investors that include In-Q-Tel, the venture capital arm of the CIA, alongside firms such as First Round Capital and IA Ventures, reflecting a dual-use technology profile that attracted national security interest (per PitchBook, 2023). The company employs a research-to-commercialization model that spans lab-scale strain engineering through pilot production to full-scale manufacturing partnerships. Its headcount is not publicly fixed but has historically oscillated around 50 to 70 full-time employees across both offices. January 2024: Announced a strategic partnership with a large-scale fermentation manufacturer to expand production capacity for its Soltellus polymer product line (per the firm, January 2024). The company also operates Lygos Agriculture, a branded division focused on biodegradable controlled-release fertilizer technologies. Lygos represents a structural case study in venture-backed industrial biomanufacturing rather than a family office. Its most distinctive architectural feature is the symbiotic relationship with the Keasling lab ecosystem and the broader UC Berkeley synthetic biology pipeline, which creates a continuous talent and intellectual property conduit rarely replicated outside academic biotech hubs. The company's governance remains founder-led with a board reflecting its hybrid venture-national security investor base, a configuration that shapes its capital allocation toward dual-use commercial applications and long-horizon infrastructure-scale manufacturing partnerships.
General information
Firm type
other
Year founded
2010
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Berkeley
Corporate office
Berkeley, CA, United States
Additional offices
Seoul, South Korea
Principals
Eric Steen
CEO and Co-Founder
Jeffrey Dietrich
CTO and Co-Founder
Jay Keasling
Co-Founder
Sector focus
Frequently asked questions
What does Lygos actually manufacture and sell today?
Lygos commercially produces bio-based malonic acid derivatives and specialty chemicals through yeast fermentation. Its publicly disclosed product lines include Soltellus, a biodegradable polymer used in personal care and water treatment, and a malonic acid-based agricultural delivery system that improves nutrient uptake in crops. The company sells these ingredients to formulators and industrial partners rather than directly to consumers.
Who are Lygos's most notable investors and what does that signal?
Lygos has raised over $230 million from a distinctive investor base that includes In-Q-Tel, the venture arm of the CIA, alongside prominent early-stage firms like First Round Capital and IA Ventures. In-Q-Tel's participation, disclosed in 2016, signals potential dual-use applications for Lygos's fermentation platform that extend beyond commercial chemical markets into areas of national security interest.
How does Lygos's technology differ from traditional chemical manufacturing?
Lygos uses engineered microorganisms — primarily yeast strains developed through synthetic biology — to convert sugars into specialty chemicals that are conventionally derived from petroleum. The process replaces energy-intensive petrochemical steps with fermentation at ambient temperatures and pressures. Its core platform focuses on malonic acid pathways, a chemical intermediate with broad industrial applications that has historically been expensive to produce via petrochemical routes.
What is Lygos's relationship with Jay Keasling's lab at UC Berkeley?
Jay Keasling is a scientific co-founder of Lygos and one of the central figures in synthetic biology, known for engineering yeast to produce artemisinin, an antimalarial drug. Lygos spun out of the Keasling Lab's metabolic engineering research program and maintains deep intellectual ties to the UC Berkeley synthetic biology ecosystem. This relationship provides a continuous pipeline of talent and foundational intellectual property, though the company operates as an independent, venture-backed entity.
Does Lygos operate any international facilities?
Yes. Lygos maintains a dual operational footprint with headquarters in Berkeley, California and an office in Seoul, South Korea. The Seoul presence supports the company's access to Asian fermentation manufacturing capacity and regional commercial partnerships for its bio-based chemical products.
What are Lygos's primary end markets?
Lygos targets three primary end markets: personal care and fragrance ingredients, agricultural nutrient delivery systems, and biodegradable polymer applications. Its agriculture division, branded Lygos Agriculture, focuses on controlled-release fertilizer technologies. The Soltellus polymer line serves formulators in water treatment and home care. These markets represent large, established chemical segments where bio-based alternatives can compete on both performance and sustainability characteristics.
Is Lygos a family office or an operating company?
Lygos is an operating company — an industrial biotechnology firm — not a family office. It is venture-backed, founder-led, and generates revenue through commercial sales of bio-based chemical products to industrial customers. The firm appears in certain alternative asset databases because of its large venture funding rounds and the crossover interest from institutional investors in synthetic biology as an asset class.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: